Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Variation in KCNQ1 is associated with therapeutic response to sulphonylureas

Zbynek Schroner, Martina Dobrikova, Lucia Klimcakova, Martin Javorsky, Jozef Zidzik, Miriam Kozarova, Terezia Hudakova, Ruzena Tkacova, Jan Salagovic, Ivan Tkac

Med Sci Monit 2011; 17(7): CR392-396

DOI: 10.12659/MSM.881850

Available online: 2011-06-21

Published: 2011-06-21

Background:    We aimed to analyse quantitative effects of treatment with sulphonylurea in addition to metformin on parameters of glycemic control in relation to KCNQ1 genotypes, and to identify factors predictive for the response to sulphonylurea treatment.
    Material/Methods:    Effect of 6-month sulphonylurea therapy in addition to metformin on glycemic control according to KCNQ1 genotypes was evaluated in 87 patients with type 2 diabetes who failed to achieve glycemic control on metformin monotherapy. KCNQ1 rs163184 (T>G) polymorphism was determined by real-time PCR with melting analysis of unlabeled probe.
    Results:    The reduction in fasting plasma glucose (ΔFPG) after 6-month sulphonylurea therapy significantly differed among 3 KCNQ1 genotype groups (ANOVA, p=0.017). In a recessive genetic model, carriers of the T-allele (TT+TG) achieved significantly lower FPG levels in comparison with patients with the GG genotype (6.95±0.13 vs. 7.50±0.21 mmol/L, p=0.033). Consequently, ΔFPG was significantly higher in the TT+TG group compared to the GG group (1.58±0.13 vs. 1.04±0.18 mmol/L, p=0.016). In multiple linear regression analysis KCNQ1 genotype (p=0.016) and baseline FPG (p<0.001) were the only significant independent predictors of ΔFPG (R2=0.48).
    Conclusions:    Our results suggest that the magnitude of FPG reduction after 6-month sulphonylurea treatment in addition to metformin in patients with type 2 diabetes is related to the variation in KCNQ1. The FPG response to sulphonylureas was significantly lower in carriers of the risk GG genotype.

Keywords: Metformin - therapeutic use, Pharmacogenetics, Linear Models, KCNQ1 Potassium Channel - metabolism, Genotype, Diabetes Mellitus, Type 2 - drug therapy, DNA Primers - genetics, Blood Glucose - analysis, Analysis of Variance, Polymerase Chain Reaction, Polymorphism, Single Nucleotide - genetics, Sulfonylurea Compounds - therapeutic use